Zydus to Enter US Biosimilar Market with Keytruda Partner
In order to sell FYB206, a biosimilar of Merck’s popular cancer medication Keytruda (pembrolizumab), in the US and Canada, Zydus Lifesciences announced on Tuesday that it has signed an exclusive license and supply deal with Germany’s Formycon AG. The action is noteworthy because the US patent for Keytruda, one of the best-selling immunotherapies in the … Read more